<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107458</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0419</org_study_id>
    <secondary_id>COG-ADVL0419</secondary_id>
    <secondary_id>NCI-05-C-0235</secondary_id>
    <secondary_id>NCI-P6631</secondary_id>
    <secondary_id>CDR0000417845</secondary_id>
    <nct_id>NCT00107458</nct_id>
  </id_info>
  <brief_title>Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors</brief_title>
  <official_title>A Phase I Study of Valproic Acid in Children With Recurrent/Progressive Solid Tumors Including CNS Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Valproic acid may also stop the growth of solid tumors or CNS tumors by blocking blood flow&#xD;
      to the tumor.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of valproic acid in&#xD;
      treating patients with recurrent or refractory solid tumors or CNS tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxic effects of valproic acid (VPA) administered at doses required to&#xD;
           maintain serum trough VPA concentrations of 100-150 mcg/mL or 150-200 mcg/mL in young&#xD;
           patients with recurrent or refractory solid tumors or CNS tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the steady-state serum trough concentration of free and total VPA at the&#xD;
           targeted total trough VPA concentration in these patients.&#xD;
&#xD;
        -  Determine the steady state histone acetylation status of peripheral blood monocytes at&#xD;
           the targeted trough VPA concentration in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Correlate histone acetylation with free or total trough VPA concentration in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      For course 1, patients receive escalating doses of oral valproic acid (VPA) twice daily until&#xD;
      a target serum trough VPA concentration range is maintained for 28 days. Patients who achieve&#xD;
      the target serum trough VPA concentration range receive subsequent courses of oral VPA twice&#xD;
      daily (at the dose found to maintain the target serum trough VPA concentration range) on days&#xD;
      1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      The first cohort of 6 patients receives VPA to achieve an initial target trough serum VPA&#xD;
      concentration. If fewer than 2 of 6 patients in the first cohort experience dose-limiting&#xD;
      toxicity (DLT), then a second cohort of 6 patients receives VPA to achieve the next higher&#xD;
      target trough serum VPA concentration. If fewer than 2 patients from the second cohort&#xD;
      experience DTL, then 6 additional patients are enrolled in this cohort to better define&#xD;
      pharmacokinetics and DLT at this VPA concentration range.&#xD;
&#xD;
      After completion of study treatment, patients are followed annually.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of oral etoposide at 50 mg/m2/day given concurrently with radiotherapy</measure>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VPA Target Trough Concentration 150-200 mcg/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproic acid</intervention_name>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_label>Treatment 10</arm_group_label>
    <arm_group_label>Treatment 20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed* malignant solid tumor, including CNS tumors, at original&#xD;
             diagnosis or relapse&#xD;
&#xD;
               -  Recurrent or refractory disease NOTE: *Histologic confirmation not required for&#xD;
                  intrinsic brain stem or optic pathway tumors&#xD;
&#xD;
          -  Measurable or evaluable disease, defined by 1 of the following criteria:&#xD;
&#xD;
               -  Any unidimensionally measurable lesion ≥ 10 mm by standard MRI or CT scan for&#xD;
                  either solid or CNS tumors&#xD;
&#xD;
               -  At least 1 nonmeasurable lesion that is evaluable by nuclear medicine,&#xD;
                  immunocytochemistry, tumor markers, cerebrospinal fluid cytology, or other&#xD;
                  reliable measures&#xD;
&#xD;
          -  No known curative therapy exists&#xD;
&#xD;
          -  No documented tumor involvement in the bone marrow&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  2 to 21&#xD;
&#xD;
        Performance status*&#xD;
&#xD;
          -  Lansky 50-100% (for patients ≤ 10 years of age)&#xD;
&#xD;
          -  Karnofsky 50-100% (for patients &gt; 10 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (transfusions allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 110 (ULN for this study is 45 U/L)&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (for patients ≤ 5 years of age)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (for patients 6 to 10 years of age)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (for patients 11 to 15 years of age)&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (for patients over 15 years of age)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Neurologic deficits in patients with CNS tumors must be stable for ≥ 1 week before&#xD;
             study entry&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known urea cycle disorders or other metabolic disorders&#xD;
&#xD;
          -  No other condition that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 7 days since prior hematopoietic growth factors that support platelet or WBC&#xD;
             number or function&#xD;
&#xD;
          -  At least 7 days since prior antineoplastic biologic agents&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue without total body&#xD;
             irradiation&#xD;
&#xD;
               -  No evidence of active graft vs host disease&#xD;
&#xD;
          -  No other concurrent anticancer biologic therapy or immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for&#xD;
             the past 7 days&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior total body irradiation, craniospinal radiotherapy, or&#xD;
             radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative small port radiotherapy&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent anticonvulsants&#xD;
&#xD;
               -  Patients receiving valproic acid (VPA) before study entry must have a total&#xD;
                  trough VPA concentration &lt; 100 mcg/mL within the past 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack M. Su, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Texas Children's Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heidi V. Russell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Texas Children's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center - Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Children's Hospital - Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-9786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, Lau CC, Adamson PC, Blaney SM. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res. 2011 Feb 1;17(3):589-97. doi: 10.1158/1078-0432.CCR-10-0738. Epub 2010 Nov 29.</citation>
    <PMID>21115653</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>August 6, 2014</last_update_submitted>
  <last_update_submitted_qc>August 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood spinal cord neoplasm</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

